Axsome settles Sunosi patent litigation with Unichem; generic entry June 30, 2042

Axsome Therapeutics, Inc.

Settlement resolves Hatch-Waxman litigation over Sunosi (solriamfetol) following Unichem's ANDA.
Unichem may begin selling generic Sunosi on June 30, 2042, subject to pediatric exclusivity extension.
Agreement subject to FTC and DOJ review; other Sunosi patent cases remain pending in New Jersey.
Axsome maintains Sunosi exclusivity until at least 2042 unless earlier triggering events occur.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.